Varied Growth Drivers Led Antipodes Global Value Strategy to Add Globus Medical (GMED) to Its Portfolio

Antipodes Partners recently published its “Antipodes Global Value Strategy” third-quarter 2025 investor letter, highlighting the key performance stocks, portfolio changes, and the market outlook. A copy of the letter can be downloaded here. In the quarter, global equities rose positively, supported by easing trade tensions, excitement around AI, and expectations of rate cuts by the Federal Reserve. Global equities gained +7.6% in USD and +6.4% in AUD, driven by central bank interest rate reductions, new US trade agreements, and strong corporate earnings. The Antipodes Global Value Strategy outperformed the benchmark during this quarter and showed even greater outperformance for the year to date and the 12 months ending September 30, 2025. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Antipodes Global Value Strategy highlighted stocks such as Globus Medical, Inc. (NYSE:GMED). Globus Medical, Inc. (NYSE:GMED) is a medical device company that focuses on the development of healthcare solutions for patients with musculoskeletal disorders. The one-month return of Globus Medical, Inc. (NYSE:GMED) was 40.97%, and its shares gained 3.56% of their value over the last 52 weeks. On November 12, 2025, Globus Medical, Inc. (NYSE:GMED) stock closed at $83.99 per share, with a market capitalization of $11.241 billion.

Antipodes Global Value Strategy stated the following regarding Globus Medical, Inc. (NYSE:GMED) in its third quarter 2025 investor letter:

“We also initiated a position in Globus Medical, Inc. (NYSE:GMED), a leading medical devices manufacturer with a top three position in spinal orthopedics devices, spinal surgical robots and trauma surgery devices. It is a pure-play operator in the spinal market, taking market share through innovation and business development to boost scale and fill product gaps. Growth is supported by structural tailwinds in spinal orthopedics including demographics, improving surgery success rates with advances in technology, expansion into orthopedic adjacencies such as knees and hips, under-penetration of robotics in spinal surgeries, and further expansion into the spinal cord stimulation market. The company has a strong balance sheet, is buying back stock and has capacity for business development to support growth.”

Globus Medical, Inc. (NYSE:GMED) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 49 hedge fund portfolios held Globus Medical, Inc. (NYSE:GMED) at the end of the second quarter, up from 45 in the previous quarter. In the third quarter of 2025, the company achieved sales of $769 million, representing growth of 22.9% compared to Q3 2024. While we acknowledge the risk and potential of Globus Medical, Inc. (NYSE:GMED) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Globus Medical, Inc. (NYSE:GMED) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Globus Medical, Inc. (NYSE:GMED) and shared the list of best mid-cap stocks with huge upside potential. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.